Nevertheless, in another meta-analysis of seven randomized trials encompassing 42,375 participants and 5 cohort studies, encompassing 318,636 participants with T2DM, SGLT2 inhibitors were found to increase the risk of ketoacidosis. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.